CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM)

Ad-RTS-hIL-12 (Ad) is a gene therapy candidate for intratumoral (IT) delivery that conditionally expresses IL-12 (IL-12) under the transcriptional control of orally administered veledimex (V) acting via the RheoSwitch Therapeutic System(â) gene switch. Increased PD-1 expression in samples of rGBM fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lukas, Rimas, Chiocca, E Antonio, Bush, Nancy Ann Oberheim, Landolfi, Joseph, Cavaliere, Robert, Yu, John, Kurz, Sylvia, Demars, Nathan, Buck, Jill, Hadar, Nira, Miao, John, Loewy, John, Wang, Yunxia, Gelb, Arnold, Cooper, Laurence
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650356/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.162
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars